熱門資訊> 正文

Geron strategic restructuring plan focuses on Rytelo growth

2025-12-17 06:49

傑龍(GERN) 0

Geron said that as part of its strategic restructuring plan, it will focus on boosting growth of anemia treatment Rytelo (imetelestat) in the US, expanding availability of the drug into other countries, and a phase 3 program of imetelestat in myelofibrosis.
Earlier in December, the company said it would lay off a third of its 260 employees as part of the plan.

More on Geron

Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help
Geron Corporation (GERN) Q3 2025 Earnings Call Transcript
Geron to lay off a third of workforce under restructuring program
Geron signals 2026 growth focus as RYTELO new patient starts rise to 36% in Q3

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。